{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:38:08Z","timestamp":1775151488665,"version":"3.50.1"},"reference-count":75,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T00:00:00Z","timestamp":1289433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Despite the fact that over 90% of HIV-1 infected people worldwide harbor non\u2011subtype B variants of HIV-1, knowledge of resistance mutations in non-B HIV-1 and their clinical relevance is limited. Due to historical delays in access to antiretroviral therapy (ART) on a worldwide basis, the vast majority of reports on drug resistance deal with subtype B infections in developed countries. However, both enzymatic and virological data support the concept that naturally occurring polymorphisms among different nonB subtypes can affect HIV-1 susceptibility to antiretroviral drugs (ARVs), the magnitude of resistance conferred by major mutations, and the propensity to acquire some resistance mutations. Tools need to be optimized to assure accurate measurements of drug susceptibility of non-B subtypes. Furthermore, there is a need to recognize that each subtype may have a distinct resistance profile and that differences in resistance pathways may also impact on cross-resistance and the selection of second-line regimens. It will be essential to pay attention to newer drug combinations in well designed long-term longitudinal studies involving patients infected by viruses of different subtypes.<\/jats:p>","DOI":"10.3390\/v2112493","type":"journal-article","created":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T10:55:00Z","timestamp":1289472900000},"page":"2493-2508","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs"],"prefix":"10.3390","volume":"2","author":[{"given":"Mark A.","family":"Wainberg","sequence":"first","affiliation":[{"name":"McGill University AIDS Centre, Jewish General Hospital, 3755 Cote-Ste-Catherine Road, Montreal, Quebec, H3T 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bluma G.","family":"Brenner","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Jewish General Hospital, 3755 Cote-Ste-Catherine Road, Montreal, Quebec, H3T 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2010,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nrmicro1594","article-title":"Is HIV-1 evolving to a less virulent form in humans?","volume":"5","author":"Arien","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00126334-200312150-00012","article-title":"Epidemiologic and molecular characterization of human immunodeficiency virus type 1 in southern Brazil","volume":"34","author":"Soares","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1097\/01.aids.0000191497.00928.e4","article-title":"HIV-1 subtype C dissemination in southern Brazil","volume":"19","author":"Soares","year":"2005","journal-title":"AIDS"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1089\/aid.2007.0121","article-title":"HIV-1 strains identified in Brazilian blood donors: Significant prevalence of B\/F1 recombinants","volume":"23","author":"Brennan","year":"2007","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/jmv.20955","article-title":"Molecular epidemiology of HIV-1 in Santa Catarina State confirms increases of subtype C in Southern Brazil","volume":"79","author":"Locateli","year":"2007","journal-title":"J. Med. Virol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/157016208785132455","article-title":"Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native Spaniards and immigrants in Spain","volume":"6","author":"Holguin","year":"2008","journal-title":"Curr. HIV Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/01.qai.0000155201.51232.2e","article-title":"French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001\u20132002","volume":"38","author":"Descamps","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/COH.0b013e32801682e2","article-title":"Resistance and viral subtypes: How important are the differences and why do they occur?","volume":"2","author":"Brenner","year":"2007","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/QCO.0b013e3280109122","article-title":"Impact of HIV-1 pol diversity on drug resistance and its clinical implications","volume":"19","author":"Kantor","year":"2006","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1089\/aid.2005.21.1031","article-title":"Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Cote d\u2019Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission","volume":"21","author":"Toni","year":"2005","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/430764","article-title":"Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP","volume":"192","author":"Eshleman","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/01.qai.0000221676.22069.b8","article-title":"Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D","volume":"42","author":"Eshleman","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1086\/499966","article-title":"Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d\u2019Ivoire","volume":"193","author":"Chaix","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":"Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated","volume":"192","author":"Johnson","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/01.qai.0000221686.67810.20","article-title":"Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D","volume":"42","author":"Flys","year":"2006","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1086\/430742","article-title":"Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012","volume":"192","author":"Flys","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_17","first-page":"212","article-title":"Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence","volume":"10","author":"Klein","year":"2008","journal-title":"AIDS Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8893","DOI":"10.1128\/jvi.71.11.8893-8898.1997","article-title":"Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses","volume":"71","author":"Descamps","year":"1997","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/00126334-200412150-00001","article-title":"Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups","volume":"37","author":"Tuaillon","year":"2004","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1574-695X.2005.00011.x","article-title":"Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients","volume":"46","author":"Vergne","year":"2006","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/01.aids.0000237368.64488.ae","article-title":"Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity","volume":"20","author":"Gifford","year":"2006","journal-title":"AIDS"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/01.aids.0000216363.36786.2b","article-title":"HIV-1 pol mutation frequency by subtype and treatment experience: Extension of the HIVseq program to seven non-B subtypes","volume":"20","author":"Rhee","year":"2006","journal-title":"AIDS"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1089\/aid.2006.0298","article-title":"The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV\/ddI-containing HAART in southern Africa","volume":"23","author":"Novitsky","year":"2007","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/QAD.0b013e328313bf87","article-title":"Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: Evidence of transmitted resistance in rural South Africa","volume":"22","author":"Barth","year":"2008","journal-title":"AIDS"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/aid.2006.0183","article-title":"Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: Resistance to AR","volume":"23","author":"Deshpande","year":"2007","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/QAD.0b013e32832ac34e","article-title":"The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy","volume":"23","author":"Hosseinipour","year":"2009","journal-title":"AIDS"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1086\/587109","article-title":"Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa","volume":"46","author":"Marconi","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1128\/AAC.00714-06","article-title":"High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens","volume":"50","author":"Avalos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/135965350901400414","article-title":"HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme","volume":"14","author":"Orrell","year":"2009","journal-title":"Antivir. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/hiv.09.40","article-title":"The K65R mutation in HIV-1 reverse transcriptase: Genetic barriers, resistance profile and clinical implications","volume":"3","author":"Brenner","year":"2009","journal-title":"HIV Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jmv.21567","article-title":"Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel","volume":"81","author":"Turner","year":"2009","journal-title":"J. Med. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/aid.2009.0217","article-title":"Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and\/or immunological WHO guidelines","volume":"26","author":"Deshpande","year":"2010","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1089\/aid.2009.0152","article-title":"Differences in HIV type 1 RNA plasma load profile of closely related cocirculating Ethiopian subtype C strains: C and C\u2032","volume":"26","author":"Ayele","year":"2010","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1097\/QAD.0b013e3283108f69","article-title":"On the origin of HIV-1 subtype C in South America","volume":"22","author":"Fontella","year":"2008","journal-title":"AIDS"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","article-title":"HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture","volume":"20","author":"Brenner","year":"2006","journal-title":"AIDS"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1086\/605894","article-title":"Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C","volume":"200","author":"Invernizzi","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/JVI.01349-08","article-title":"Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1","volume":"83","author":"Coutsinos","year":"2009","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3851\/IMP1443","article-title":"Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1","volume":"20","author":"Coutsinos","year":"2010","journal-title":"Antivir. Chem. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1097\/QAD.0b013e328318f16c","article-title":"Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency","volume":"22","author":"Harrigan","year":"2008","journal-title":"AIDS"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Varghese, V., Wang, E., Babrzadeh, F., Bachmann, M.H., Shahriar, R., Liu, T., Mappala, S.J., Gharizadeh, B., Fessel, W.J., and Katzenstein, D. (2010). Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010992"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"D\u2019Aquila, R.T., Geretti, A.M., Horton, J.H., Rouse, E., Kheshti, A., Raffanti, S., Oie, K., Pappa, K., and Ross, L.L. (2010). Tenofovir (TDF)-Selected or Abacavir (ABC)-Selected Low-Frequency HIV Type 1 Subpopulations during Failure with Persistent Viremia as Detected by Ultradeep Pyrosequencing. AIDS Res. Hum. Retrovirus.","DOI":"10.1089\/aid.2010.0077"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zolfo, M., Schapiro, J., Phan, V., Koole, O., Thai, S., Vekemans, M., Fransen, K., and Lynen, L. (2010). Genotypic impact of prolonged detectable HIV-1 RNA viral load after HAART failure in a CRF01_AE infected cohort. AIDS Res. Hum. Retrovirus.","DOI":"10.1089\/aid.2010.0037"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1097\/01.aids.0000189860.36688.e5","article-title":"K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients","volume":"19","author":"Gupta","year":"2005","journal-title":"AIDS"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/QAI.0b013e318182d2bc","article-title":"HIV drug resistance pattern among HAART-exposed patients with suboptimal virological response in Ouagadougou, Burkina Faso","volume":"49","author":"Tebit","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1128\/AAC.46.7.2087-2094.2002","article-title":"Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT","volume":"46","author":"Loemba","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","article-title":"A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors","volume":"17","author":"Brenner","year":"2003","journal-title":"AIDS"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00126334-200501010-00002","article-title":"Characterization of mutations in CRF01_AE virus isolates from antiretroviral treatment-naive and -experienced patients in Singapore","volume":"38","author":"Hsu","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1089\/aid.2009.0110","article-title":"Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients","volume":"25","author":"Rajesh","year":"2009","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00002030-200404090-00008","article-title":"Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C","volume":"18","author":"Grossman","year":"2004","journal-title":"AIDS"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1128\/AAC.00829-10","article-title":"Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors","volume":"54","author":"Lai","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00126334-200307010-00007","article-title":"Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection","volume":"33","author":"Ariyoshi","year":"2003","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1097\/01.inf.0000190413.88671.92","article-title":"Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Cote d\u2019Ivoire","volume":"24","author":"Chaix","year":"2005","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijantimicag.2007.10.029","article-title":"Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: Impact of polymorphism on resistance to therapy","volume":"31","author":"Sukasem","year":"2008","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1128\/AAC.48.6.2159-2165.2004","article-title":"Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir","volume":"48","author":"Grossman","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1128\/AAC.01447-05","article-title":"Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen","volume":"50","author":"Avalos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1086\/382483","article-title":"Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance","volume":"189","author":"Dumans","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1086\/430002","article-title":"Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism","volume":"191","author":"Calazans","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1128\/AAC.01828-09","article-title":"HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes","volume":"54","author":"Lisovsky","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jmgm.2010.05.007","article-title":"Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations","volume":"29","author":"Soares","year":"2010","journal-title":"J. Mol. Graph. Model."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1128\/AAC.48.9.3552-3555.2004","article-title":"Impact of nelfinavir resistance mutations on in vitro phenotype, fitness, and replication capacity of human immunodeficiency virus type 1 with subtype B and C proteases","volume":"48","author":"Gonzalez","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","first-page":"25","article-title":"Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution","volume":"5","author":"Kantor","year":"2003","journal-title":"AIDS Rev."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kantor, R., Katzenstein, D.A., Efron, B., Carvalho, A.P., Wynhoven, B., Cane, P., Clarke, J., Sirivichayakul, S., Soares, M.A., and Snoeck, J. (2005). Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020112"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Soares, E.A., Santos, A.F., Sousa, T.M., Sprinz, E., Martinez, A.M., Silveira, J., Tanuri, A., and Soares, M.A. (2007). Differential drug resistance acquisition in HIV-1 of subtypes B and C. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000730"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1089\/aid.2009.0012","article-title":"Primary antiretroviral drug resistance among HIV type 1-infected individuals in Brazil","volume":"25","author":"Sprinz","year":"2009","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_66","first-page":"71","article-title":"The HIV-1 Non-subtype B Workgroup: An international collaboration for the collection and analysis of HIV-1 non-subtype B data","volume":"7","author":"Kantor","year":"2005","journal-title":"MedGenMed"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/596504","article-title":"Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: Implications for HIV-2 treatment in resouce-limited West Africa","volume":"48","author":"Gottlieb","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1128\/AAC.00154-09","article-title":"Antiretroviral drug resistance in human immunodeficiency virus type 2","volume":"53","author":"Ntemgwa","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/135965350801300116","article-title":"Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso","volume":"13","author":"Sylla","year":"2008","journal-title":"Antivir. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/431197","article-title":"HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors","volume":"41","author":"Kinomoto","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/aid.2006.22.357","article-title":"Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: Comparative genotypic and phenotypic data","volume":"22","author":"Fleury","year":"2006","journal-title":"AIDS Res. Hum. Retrovirus."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"8613","DOI":"10.1021\/bi020160i","article-title":"Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes","volume":"41","author":"Vega","year":"2002","journal-title":"Biochemistry"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"564","DOI":"10.7326\/0003-4819-146-8-200704170-00007","article-title":"Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes","volume":"146","author":"Nachega","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/088922204323048104","article-title":"High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1","volume":"20","author":"Richard","year":"2004","journal-title":"AIDS Res Hum Retrovirus."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-4690-6-14","article-title":"Effects of the K65R and K65R\/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance","volume":"6","author":"Xu","year":"2009","journal-title":"Retrovirology"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/11\/2493\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:03:49Z","timestamp":1760220229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/11\/2493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,11]]},"references-count":75,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2010,11]]}},"alternative-id":["v2112493"],"URL":"https:\/\/doi.org\/10.3390\/v2112493","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,11]]}}}